Le virus humain T lymphotrope de type 1 (HTLV-1) est l’agent étiologique de la leucémie/lymphome T de l’adulte (ATLL) qui se développe après plusieurs décennies et pour laquelle il n’existe à ce jour pas de traitement efficace. Parmi les protéines virales de HTLV-1, Tax et HBZ jouent un rôle déterminant dans le développement de l’ATLL. Si Tax participe au processus leucémogène dès les étapes précoces, HBZ jouerait plutôt un rôle dans le maintien du phénotype tumoral dans les étapes tardives. Dans ce contexte, là nous nous sommes intéressés à la régulation de l’expression des protéines anti-apoptotiques Bfl-1 et Bcl-xL, par les protéines virales Tax et HBZ. Nous avons montré que Tax induit l’expression des protéines anti-apoptotiques Bfl-1 et Bcl-xL de la famille Bcl-2 via la voie NF-κB, alors que HBZ n’a aucun effet sur leur expression. De plus, Tax coopère avec les facteurs de transcription c-Jun et JunD de la voie AP-1 pour augmenter l’expression de ces gènes anti-apoptotiques. En revanche, HBZ module uniquement la trans-activation de bfl-1 induite par Tax. L’ensemble de nos résultats indique donc que Tax joue un rôle prépondérant dans l’activation de l’expression de Bfl-1 et de Bcl-xL et suggère que Bfl-1 et Bcl-xL sont exprimées au cours des étapes précoces et tardives du développement de l’ATLL. Par une stratégie d’ARN interférence, nous avons ensuite montré que Bfl-1 et/ou Bcl-xL sont impliquées dans la survie de lignées cellulaires T infectées par HTLV-1, suggérant que Bfl-1 et Bcl-xL représentent des cibles thérapeutiques potentielles pour traiter l’ATLL. Actuellement, il existe des petites molécules ciblant les membres anti-apoptotiques de la famille Bcl-2, mais aucune ne cible spécifiquement Bfl-1. En collaboration avec la société IMAXIO, nous avons identifié par deux cribles à haut débit 83 molécules capables d’inhiber l’activité anti-apoptotique de Bfl-1. L’une de ces molécules induit spécifiquement la mort de lignées cellulaires T infectées par HTLV-1 pour lesquelles Bfl-1 représente un gène de survie. Ainsi, ce travail doit permettre à terme de développer de futurs médicaments dirigés contre Bfl-1 et de proposer une nouvelle stratégie thérapeutique ciblée contre l’ATLL / Human T lymphotropic virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia/lymphoma (ATLL) that develops after several decades and for which there is no effective treatment. Among the viral proteins of HTLV-1, Tax and HBZ play a major role in the development of ATLL. If Tax participates in the initiation of leukemogenesis from the early stages, HBZ rather plays a role in maintaining the tumor phenotype in the late stages. The aims of our study were to better understand the regulation of Bfl-1 and Bcl-xL anti-apoptotic protein expression by Tax and HBZ viral proteins, as well as their role in the survival of HTLV-1-infected T-cells to propose new therapeutic strategies. We showed that Tax induces Bfl-1 and Bcl-xL expression via the NF-κB pathway, whereas HBZ has no effect on their expression. Tax also cooperates with c-Jun and JunD transcription factors of AP-1 family to increase the expression of these anti-apoptotic genes. By contrast, HBZ modulates the Tax-induced bfl-1 trans-activation. Altogether, our data indicate that Tax plays a key role in activating Bfl-1 and Bcl-xL expression and suggests that Bfl-1 and Bcl-xL are potentially expressed during the early and the late stages of ATLL development. Using short hairpin RNA strategy, we then showed that Bfl-1 and/or Bcl-xL are involved in HTLV-1-infected T-cell line survival, indicating that Bfl-1 and Bcl-xL represent potential therapeutic targets in the case of ATLL. One approach currently being developed in anti-cancer drug discovery is to search for small inhibitory compounds targeting anti-apoptotic proteins of the Bcl-2 family. But so far, no drug specifically targeting Bfl-1 is available. In collaboration with the IMAXIO Company, we have identified 83 molecules able to inhibit Bfl-1 anti-apoptotic activity using two high-throughput screening. One of these molecules specifically induced the death of HTLV-1-infected T-cell for which Bfl-1 represents a survival gene. This work provides new insight for long-term development of future drugs directed against Bfl-1 and should allow us to propose new therapeutic strategy for ATLL treatment

Thesis summary The process of B cell lymphogenesis in swine remains uncertain. Some reports indicate that pigs belong to a group of animal that use ileal Peyers's patches (IPP) for the generation of B cells while others point to the possibility that the bone marrow is functional throughout life. The functional subpopulations of B cells in swine are also unknown. Together with other ruminants, and also birds, γδ T cells in swine may account for >70% of all T cells which is in apparent contrast with humans and mice. The purpose of this thesis was to address these discrepancies and unresolved issues. The results disprove the existing paradigm that the IPP is primary lymphoid tissue and that B cells develop in IPP in an antigen-independent manner. On the other hand, it shows that bone marrow is fully capable of B cell lymphogenesis and remains active at least for the same period of time as it had been speculated for the IPP. This thesis also identified functionally different subsets of porcine peripheral B cells, and shows that CD21 molecules can be expressed in differential forms. Finally, this thesis identifies two lineages of γδ T cells that differ in many functional and phenotype features. This finding may explain why γδ T cells constitute of minority of lymphocytes in circulation of humans and mice.

O timo é um órgão linfoide primário, localizado em região mediastinal, cuja importância funcional é a diferenciação e maturação de todas as subpopulações de linfócitos T provenientes da medula óssea assim como a seleção de células autorreativas. Sua hipoplasia ou aplasia resultam em síndromes de imunodeficiência. Embora de vital importância, o estudo clínico de sua função não é rotineiro na prática clínica, o que pode ser atribuído a sua dificuldade de avaliação em razão de sua localização, necessidade de uso de métodos de imagem não inócuos ao paciente (tomografia computadorizada (TC), PET-SCAN) e complexidade das análises em sangue periférico de subpopulações de células T por citometria de fluxo e, mais recentemente, medição de T cell receptor excision circles (TRECs), por PCR. Um possível método da avaliação do timo sem radiação ionizante ou dor ao paciente seria a elastografia de timo por ultrassom e seu uso na prática clínica poderia substituir a TC, como ocorre na avaliação de lesões hepáticas ou mamárias. Objetivo - Este estudo se propõe a 1. Implantar este método na avaliação da função tímica, 2. Estabelecer valores de referência de TRECs na faixa etária estudada, 3. Investigar se há correlação entre os dois parâmetros. Métodos - Foram incluídas sessenta e quatro crianças de 0-5 anos em acompanhamento no ambulatório de cirurgia infantil sem doença sistêmica ou infecção aguda, e que iriam coletar amostra de sangue para exames pré-operatórios. Quarenta e oito destas coletaram amostra de sangue para avaliação de TRECs, vinte e nove realizaram elastografia num mesmo momento, porém apenas 13 destas apresentaram resultado confiável. A média da idade foi de 36 ± 16meses, predomínio do grupo foi masculino (75%), nascidos a termo (72%) e a principal intervenção cirúrgica foi do tipo urológica de pequeno porte. A elastografia mostrou média de 1,21 ± 0,24m/s, sem diferença significativa quando comparada ano a ano. Observamos uma média de TRECs de 195,6 ± 120,5 cópias/µL, mostrando valores significativamente mais altos quando comparados a adolescentes hígidos da base de dados do laboratório. Os valores de TRECs observados mostram uma ampla variabilidade na faixa etária estudada, sem diferença significativa quando separados por idade ano a ano. Não se encontrou correlação significativa entre a dureza do timo analisada à elastografia e valores de TRECs em sangue periférico. Concluímos que a elastografia é um método que possibilita a avaliação das dimensões e função do timo em crianças a partir de 2 anos de idade, entretanto estudos adicionais são necessários para que se possa recomendar a larga implantação deste método com essa finalidade / The thymus is a primary lymphoid gland responsible for the maturation of T cells as well as the immunological central tolerance. It has been a neglected organ by physicians, despite its relevance in early immunity. Thymic function can be indirectly measured by Computerized Tomography imaging and PET SCAN, T cell subpopulation flow cytometry. More recently, in the beginning of this century, a direct measurement represented by TRECs (T cell receptors excision circles) was developed. Classical thymic imaging has used ionized radiation, which poses a major risk for the pediatric patient and new techniques are needed. Objectives and methods - In this work, we tested the use of elastography ultrasound for the evaluation of the thymus in a group of < 5-year- old healthy children. In parallel, we measured TRECs in peripheral blood and compared the values obtained from both methods. We have reached sixty-four children at the pediatric surgery outpatients ambulatory, scheduled for minor surgeries. A sample of blood was taken during pre operatory and then patients were sent to the imaging service for elastography. Of all, sixty-four had undertaken TRECs and seventeen, elastography. The median age was 36 ±16 months and we had 75% of boys for surgical correction of urologic minor defects. The elastography results showed a median of 1.2 ± 0.24 m/s in all ages, the same stiffness as the liver, as shown in other works. Our median TREC/µL value was 195.6 ± 120.5 copies/µL showing a trend of reduction in older ages, and with statistical significance when compared with healthy teenagers\' values from the lab database. We concluded that elastography may be a good diagnostic tool for thymus evaluation, and additional works are needed for its recommendation in clinical practice. Our TRECs values showed a large variability, as also demonstrated in previous works, and a trend of reduction over age. We could not observe any significant correlation between elastography and TRECs values

O timo é um órgão linfoide primário, localizado em região mediastinal, cuja importância funcional é a diferenciação e maturação de todas as subpopulações de linfócitos T provenientes da medula óssea assim como a seleção de células autorreativas. Sua hipoplasia ou aplasia resultam em síndromes de imunodeficiência. Embora de vital importância, o estudo clínico de sua função não é rotineiro na prática clínica, o que pode ser atribuído a sua dificuldade de avaliação em razão de sua localização, necessidade de uso de métodos de imagem não inócuos ao paciente (tomografia computadorizada (TC), PET-SCAN) e complexidade das análises em sangue periférico de subpopulações de células T por citometria de fluxo e, mais recentemente, medição de T cell receptor excision circles (TRECs), por PCR. Um possível método da avaliação do timo sem radiação ionizante ou dor ao paciente seria a elastografia de timo por ultrassom e seu uso na prática clínica poderia substituir a TC, como ocorre na avaliação de lesões hepáticas ou mamárias. Objetivo - Este estudo se propõe a 1. Implantar este método na avaliação da função tímica, 2. Estabelecer valores de referência de TRECs na faixa etária estudada, 3. Investigar se há correlação entre os dois parâmetros. Métodos - Foram incluídas sessenta e quatro crianças de 0-5 anos em acompanhamento no ambulatório de cirurgia infantil sem doença sistêmica ou infecção aguda, e que iriam coletar amostra de sangue para exames pré-operatórios. Quarenta e oito destas coletaram amostra de sangue para avaliação de TRECs, vinte e nove realizaram elastografia num mesmo momento, porém apenas 13 destas apresentaram resultado confiável. A média da idade foi de 36 ± 16meses, predomínio do grupo foi masculino (75%), nascidos a termo (72%) e a principal intervenção cirúrgica foi do tipo urológica de pequeno porte. A elastografia mostrou média de 1,21 ± 0,24m/s, sem diferença significativa quando comparada ano a ano. Observamos uma média de TRECs de 195,6 ± 120,5 cópias/µL, mostrando valores significativamente mais altos quando comparados a adolescentes hígidos da base de dados do laboratório. Os valores de TRECs observados mostram uma ampla variabilidade na faixa etária estudada, sem diferença significativa quando separados por idade ano a ano. Não se encontrou correlação significativa entre a dureza do timo analisada à elastografia e valores de TRECs em sangue periférico. Concluímos que a elastografia é um método que possibilita a avaliação das dimensões e função do timo em crianças a partir de 2 anos de idade, entretanto estudos adicionais são necessários para que se possa recomendar a larga implantação deste método com essa finalidade / The thymus is a primary lymphoid gland responsible for the maturation of T cells as well as the immunological central tolerance. It has been a neglected organ by physicians, despite its relevance in early immunity. Thymic function can be indirectly measured by Computerized Tomography imaging and PET SCAN, T cell subpopulation flow cytometry. More recently, in the beginning of this century, a direct measurement represented by TRECs (T cell receptors excision circles) was developed. Classical thymic imaging has used ionized radiation, which poses a major risk for the pediatric patient and new techniques are needed. Objectives and methods - In this work, we tested the use of elastography ultrasound for the evaluation of the thymus in a group of < 5-year- old healthy children. In parallel, we measured TRECs in peripheral blood and compared the values obtained from both methods. We have reached sixty-four children at the pediatric surgery outpatients ambulatory, scheduled for minor surgeries. A sample of blood was taken during pre operatory and then patients were sent to the imaging service for elastography. Of all, sixty-four had undertaken TRECs and seventeen, elastography. The median age was 36 ±16 months and we had 75% of boys for surgical correction of urologic minor defects. The elastography results showed a median of 1.2 ± 0.24 m/s in all ages, the same stiffness as the liver, as shown in other works. Our median TREC/µL value was 195.6 ± 120.5 copies/µL showing a trend of reduction in older ages, and with statistical significance when compared with healthy teenagers\' values from the lab database. We concluded that elastography may be a good diagnostic tool for thymus evaluation, and additional works are needed for its recommendation in clinical practice. Our TRECs values showed a large variability, as also demonstrated in previous works, and a trend of reduction over age. We could not observe any significant correlation between elastography and TRECs values

Le carcinome séreux de haut grade (CSHG) est le sous-type de cancer de l'ovaire le plus agressif et mortel. Alors qu'une meilleure survie globale des patientes soit associée à une infiltration lymphocytaire, l'immunothérapie par blocage des points de contrôle immunitaires a obtenu des résultats limités, témoignant ainsi l'importance de comprendre le fonctionnement du système immunitaire au sein de ces tumeurs malignes. L’immunologie des tumeurs intègre des cellules immunitaires innées et adaptatives et utilise des médiateurs inflammatoires pour ajuster finement l'ampleur et la durée de la réponse immunitaire. Ainsi, cette thèse a pour objectif de définir l'hétérogénéité des cellules immunitaires intratumorales et périphériques chez les patientes atteintes d'un cancer de l'ovaire mais aussi à explorer les mécanismes de la réponse immunitaire. En combinant des techniques de biologie computationnelle et de séquençage de l'ARN à cellule unique nous avons pu identifier les différents composants du système immunitaire des patientes atteintes d'un cancer de l'ovaire mais aussi valider nos résultats dans une plus large cohorte associant d'autres types de cancer. Dans un premier temps, nous avons étudié l'un des médiateurs de l'inflammation, la voie de signalisation extracellulaire de l'adénosine. Nous avons évalué l'impact de cette voie de signalisation sur la survie des patientes atteintes de CSHG et identifié les cellules du microenvironnement tumoral participant au fonctionnement de cette voie. Ensuite, nous avons concentré notre étude sur la dynamique des lymphocytes T et identifié leurs états cellulaires associés, déduit leur relation développementale et étudié les changements transcriptionnels déclenchés par les interactions entre les cellules dans le microenvironnement immunitaire tumoral. Nous avons démontré que les cellules de type Tfh produisent le médiateur 7α,25 dihydroxycholestérol (7α,25-HC) décrit comme régulant le positionnement des cellules immunitaires dans les organes lymphoïdes secondaires. Ainsi, notre étude suggère que les cellules de type Tfh utilise ce mécanisme pour recruter des lymphocytes T CD8 pré-effecteurs/prédysfonctionnels et des cellules dendritiques plasmacytoïdes dans les tumeurs. Finalement, nos résultats indiquent que les cellules de type Tfh exprimant l'interleukine-21 aident à promouvoir l'immunité antitumorale contre les tumeurs ovariennes en coordonnant l'action des lymphocytes et des cellules dendritiques plasmacytoïdes sensibles au 7α,25-HC. En conclusion, nos travaux de recherche ont permis d’identifier des vulnérabilités dans le microenvironnement immunitaire tumoral pouvant être ciblées dans la thérapie contre le CSHG. / High-grade serous ovarian carcinoma (HGSOC) is the most aggressive and lethal subtype of ovarian cancer. Although better overall survival is associated with lymphocytic infiltration, immunotherapy by immune checkpoint blockades achieved modest results, reinforcing the importance of understanding immunity in this malignancy. Cancer immunity integrates innate and adaptive immune cells and makes use of inflammatory mediators to finely tune the magnitude and duration of the immune response. This thesis aims to reveal the heterogeneity of intratumoral and peripheral immune cells in ovarian cancer patients and explore the mechanisms of the immune response. For this purpose, we have used the high-resolution technology of single-cell RNAsequencing and computational biology to immune profile HGSOC patients. Firstly, we explored one of the mediators of inflammation, the immunosuppressive extracellular adenosine (eADO). The ectonucleotidases CD73 and CD39 regulate the eADO signaling pathway, and their expression is prognostic in several cancer types. Since their role in HGSOC was yet largely unexplored, we hypothesized that a transcriptomic meta-analysis of eADO signaling pathway would provide the clinical impact of the pathway in this malignancy. We analyzed the transcriptome of approximately 1200 HGSOC patients to evaluate the effect of CD39 and CD73 on clinical outcomes. While high expression of both ectonucleotidases was associated with worse overall survival in HGSOC, only CD39 was associated with chemoresistance, supporting the evaluation of eADO-targeting agents in HGSOC. Subsequently, we investigated T cell dynamics. Because T cell clones expanded in both tumor and peripheral tissue associated with response to ICB, we hypothesized that the tumor immune microenvironment (TIME) modulates their function and, therefore, analysis of cell-cell interaction would identify the cells participating in this process. Thus, we identified T cell states, inferred their developmental relationship, and studied transcriptional changes triggered by cellcell interactions in the TIME. We demonstrated that exhausted CD8 T cells highly expressed the chemokines CCL4 and XCL1, previously described in the priming of CD8 T cells in secondary lymphoid organs (SLOs). Finally, we proposed that the lipid mediator 7α,25 dihydroxycholesterol (7α,25-HC), only described in SLOs, may also modulate cell-cell interactions in the tumor immune microenvironment. Collectively, our studies propose strategies to modulate TIME in HGSOC targeting the adenosine pathway and oxysterols metabolites.

No description available.

CD8+ T Zellen unterstützen die Beseitigung von Pathogenen und sind somit entscheidend bei der Bekämpfung von Infektionen. Neben der Antigendosis und dem inflammatorischen Zytokinemilieu hat auch die Stimulation durch den TZR einen entscheidenden Einfluss auf die CD8+ T Zellantwort. Das transkriptionelle Programm, die finale Größe und Dauer der klonalen Expansion und der Start der Kontraktionsphase werden durch die TZR-Signalstärke bestimmt. Schwache TZR-Stimulation führt zu einer verminderten Expansion und vermittelt eine frühzeitige Kontraktionsphase, die eine Entwicklung von Gedächtniszellen auf den Kosten der Effektorzellen favorisiert. IRF4 wird nach TZR-Ligand-Interaktion in CD8+ T-Zellen hoch reguliert. Seine Expressionskinetik ist stark von der TZR-Signalstärke der Aktivierung abhängig, übersetzt diese und sorgt für die Umsetzung in ein entsprechendes transkriptionelles und differentielles Programm. In dieser Arbeit konnte erstmals gezeigt werden, dass die IRF4-Defizienz in CD8+ T-Zellen zu einem verfrühten Abbruch der Expansion und zu einem vorzeitigen Beginn der Kontraktion führt, die durch den FAS-vermittelten Tod-induzierenden Signalweg initiiert wird. Außerdem präsentieren IRF4-defiziente CD8+ T-Zellen vermehrt Phosphatidylserine an ihrer Oberfläche und Komplementdeposition, beides begünstigt die Erkennung und Aufnahme durch Phagozyten. Diese Ergebnisse weisen zudem stark darauf hin, dass durch die fehlende Expression von IRF4 in CD8+ T Zellen, ein schwaches TZR-Signal übermittelt wird, unabhängig von der tatsächlichen Stärke und Dauer des aktivierenden Signals, dass zu einer Verkürzung der Expansionsphase führt und eine verfrühte Kontraktionsphase der Effektorzellen auslöst. Diese Arbeit erweitert schon bekanntes Wissen um IRF4 als Schlüsselregulator für die Differenzierung und Funktionalität der ag-spezifischen CD8+ T-Zellen, da es den Beginn der Kontraktionsphase diktiert mittels Aktivierung von verschiedenen Apoptose- und Phagocytose Signalwegen. / CD8+ T cells promote pathogen clearance and play a crucial role in controlling infections. Besides antigen dose and inflammatory cytokine milieu, the TCR stimulation contributes to the programming of the CD8+ T cell response. A distinct developmental program, the final magnitude and duration of clonal expansion, as well as the timing of the onset of T cell contraction, are determined by the TCR signaling strength. Weak TCR stimulation results in a diminished magnitude of expansion and accelerates the onset of contraction, as it favors the development of memory cells at the expense of effector cells. IRF4 is a transcription factor, that is upregulated in CD8+ T cells following TCR stimulation. Furthermore, its expression kinetic is highly dependent on the TCR signaling strength, which initiated activation. Therefore, it translates the strength of the activating signal and transmits it into a proper transcriptional and developmental program. This study provides unique evidence that the absence of IRF4 expression in CD8+ T cells leads to a hasted termination of clonal expansion and a premature contraction, initiated by the FAS-mediated cell death pathway. Moreover, IRF4-deficient CD8+ T cells exposed phosphatidylserine on their cell surface and showed complement deposition, both facilitating their recognition and uptake by phagocytes. The findings of this study additionally strongly indicate that IRF4 deficiency mimics weak TCR engagement and in turn transmits every TCR signal, independent of its actually affinity and duration, into a developmental program, that give rise to an early memory formation and results in a premature onset of effector CD8+ T cell contraction. This data extend previous knowledge of IRF4 being essential for the differentiation and functionality of ag-specific effector CD8+ T cells, as it furthermore dictates the onset of CD8+ T cell contraction via the activation of several death and phagocytosis inducing pathways.

Durch den Transfer der Gene des heterodimeren T-Zellrezeptors (TZR) mithilfe viraler Vektoren können T-Zellen programmiert werden, ein ausgewähltes Antigen spezifisch zu erkennen. In klinischen Studien wurden solche T-Zellen bereits mit Erfolg zur Immuntherapie von Krebs und viralen Infektionen eingesetzt. Genmodifizierte T-Zellen unterscheiden sich jedoch von normalen T-Zellen, weil sie neben den beiden zelleigenen auch die zwei übertragenen TZR-Gene exprimieren. Diese Situation erlaubt die Bildung vier verschiedener TZR-Heterodimere: der zelleigene TZR, der übertragene TZR und zwei gemischte TZR, bestehend aus je einer übertragenen und einer zelleigenen TZR-Kette. Gemischte TZR bergen das Risiko von Nebenwirkungen, weil sie durch Zufall gesundes Körpergewebe erkennen und so Autoimmunität auslösen könnten. In dieser Arbeit wurden deshalb virale Vektoren entwickelt, die gleichzeitig mit der Übertragung von neuen TZR-Genen den zelleigenen TZR durch RNA Interferenz (RNAi) unterdrücken. Mikro-RNA (miRNA), die in den Vektor MP71 eingefügt wurden, reduzierten den zelleigenen TZR in Maus-T-Zellen um mehr als 85%. Dies hatte zur Folge, dass beide Ketten des übertragenen P14-TZR in gleicher Menge auf der Zelloberfläche exprimiert wurden und die Bildung von gemischten TZR reduziert wurde. In einem Mausmodell der adoptiven T-Zelltherapie verhinderte die Unterdrückung des zelleigenen TZR die Entstehung von Autoimmunität, die andernfalls durch gemischte TZR verursacht wurde. Im Gegensatz dazu führte die Anwendung von gentechnisch optimierten P14-TZR-Genen weder zur angeglichenen Oberflächenexpression der P14-TZR Ketten noch zu weniger Autoimmunität im Mausmodell. Ein anderes Tierexperiment zeigte, dass die miRNA die Funktion der genmodifizierten T-Zellen nicht beeinträchtigte. Schließlich wurde ein viraler Vektor entwickelt und getestet, der die Expression des zelleigenen TZR in menschlichen T-Zellen effektiv unterdrückte und die Bildung von gemischten TZR reduzieren konnte. / T cells can be genetically modified using viral vectors. The transfer of genes encoding both chains of the heterodimeric T cell receptor (TCR) programs T cells to specifically react towards an antigen of choice. Such TCR gene-modified T cells were already successfully applied in clinical studies to treat cancer and viral infections. However, in contrast to nonmanipulated T cells these cells express the transferred TCR in addition to the endogenous TCR and this situation allows the assembly of four different TCR heterodimers: the endogenous TCR, the transferred TCR, and two mixed TCR dimers, composed of one endogenous and one transferred TCR chain. The formation of mixed TCR dimers represents a safety issue because they may by chance recognize self-antigens and thereby cause autoimmune side effects. To overcome this problem, an RNAi-TCR replacement vector was developed that simultaneously silences the endogenous TCR and expresses an RNAi-resistant therapeutic TCR. The expression of miRNA encoded by a retroviral MP71 vector in transduced mouse T cells reduced the surface levels of the endogenous TCR by more than 85%. The knockdown of the endogenous TCR in turn resulted in equal surface expression levels of both transferred P14 TCR chains and prevented the formation of mixed TCR dimers. Accordingly, the development of lethal mixed TCR dimer-dependent autoimmunity (TI-GVHD) in a mouse model of adoptive T cell therapy was dramatically reduced by the knockdown of the endogenous TCR. In contrast, the usage of genetically optimized TCR genes neither resulted in equal surface levels of both P14 TCR chains nor in reduced autoimmunity. A second mouse model demonstrated that the in vivo functionality of the transduced T cells was not negatively influenced by the expression of the miRNA. Finally, an RNAi-TCR replacement vector for human T cells was developed that effectively reduced the expression of the endogenous TCR and prevented the formation of mixed TCR dimers.

Multiple Sklerose (MS) ist eine heterogene Krankheit des Zentralnervensystems, deren pathologische Mechanismen noch nicht vollständig aufgeklärt sind. Die gegenwärtige Hypothese ist, daß pro-inflammatorische T-Zellen entscheidend an der Pathogenese der MS beteiligt sind. Man geht davon aus, daß eine Fehlregulation der T-Zell-Kontrolle, möglicherweise bedingt durch ein Ungleichgewicht an Apoptose-regulierenden Molekülen, dabei eine Rolle spielt. Tatsächlich zielen therapeutische Strategien darauf ab, T-Zell-Aktivierung, Proliferation und Produktion von Zytokinen zu verringern, oder T-Zell-Eliminierung zu fördern. Diese Arbeit sollte zum einen die Bedeutung regulatorischer Faktoren klären, die für das überleben der T-Zellen von MS-Patienten verantwortlich sind. Zum anderen sollten die antiproliferative oder Apoptose-fördende Wirkung potentiell therapeutisch wirksamer Moleküle untersucht werden. Eine eingeschränkte Regulation der autoreaktiven T-Zellen durch Apoptose in der Peripherie und im ZNS trägt möglicherweise zur Pathophysiologie der MS bei. Als Schlüsselfaktoren der Regulation von Apoptose wurden Mitglieder der Bcl-2-Familie in MS-Patienten und Probanden untersucht. Diese Faktoren wurden in Relation zu der Suszeptibilität der T-Zellen gegenüber aktivierungsinduziertem Zelltod (sog. Activation-induced cell death oder AICD) überprüft. Um die in-vivo-Elimination der Antigen-reaktiven T-Zellen nachzuahmen, wurde ein in-vitro-Modell des AICD mit repetitiver T-Zell-Stimulation verwendet. Tatsächlich zeigten polyklonale T-Zellen von MS-Patienten eine verringerte Suszeptibilität für AICD, nachgewiesen sowohl durch verminderte Caspaseaktivtät (p=0.013) als auch durch DNA-Fragmentierung (p=0.0071). Weiter wurden höhere Spiegel des Proteins Bcl-XL in den Immunzellen von MS-Patienten mit Immunoblotting gemessen (p=0.014). Eine inverse Korrelation zwischen der Expression an Bcl-XL und der Empfindlichkeit der T-Zellen gegenüber AICD steht in Übereinstimmung mit vorhergehenden Daten bezüglich der Bedeutung dieses Proteins für die Apoptose-Resistenz von T-Zellen. Es wurde bereits gezeigt, daß dieses Molekül die Ausprägung der experimentell-autoimmun Enzephalomyelitis, des Tiermodells der MS, verstärkt. Zusammen mit den erhöhten Bcl-XL-Werten bei MS-Patienten, ergeben sich nun Perspektiven für einen therapeutischen Ansatz. Abgesehen von dem Konzept die apoptotische Eliminierung von T-Zellen zu unterstützen, streben gegenwärtige therapeutische Strategien an, die Aktivierung und weitere Proliferation der schädlichen T-Zellen zu hemmen. Basierend auf klinischer Erfahrung mit eher unselektiven Therapien, ist es ein therapeutisches Ziel, neue immunomodulatorische Substanzen mit besserer Selektivität zu finden, um das Nutzen/Risiko-Verhältnis zu maximieren. Aus diesem Grund wurden zwei unterschiedliche Substanzen untersucht die beide den Zellzyklus beeinflussen. Als erster Kandidat wurde der kürzlich entdeckte Todesligand TRAIL (engl.: TNF-related apoptosis inducing ligand) aus der TNF/NGF-Familie untersucht, da diesem bereits T-Zell-regulatorische Funktionen zugeschrieben worden waren, humane Antigen-spezifische T-Zellen jedoch resistent gegenüber TRAIL-induzierter Apoptose sind. Der zweite Kandidat mit potenziell therapeutischer Wirkung bei MS ist Atorvastatin, ein HMG-CoA-Reduktase-Hemmer, der bereits als Lipidsenker bei Patienten eingesetzt wird. Um die Hypothese zu überprüfen, daß diese Substanzen T-Zell-Rezeptor-Signale beeinflussen können, wurden humane Antigen-spezifische T-Zell-Linien von MS-Patienten und gesunden Probanden eingesetzt. Diese wurden hinsichtlich T-Helfer-Phänotyp und Peptid-Spezifität charakterisiert. Eine Behandlung mit TRAIL führte zur Hemmung der Proliferation in unterschiedlichem Ausmaß (6.2% - 63.8%). Atorvastatin hemmte in Abhängigkeit von der Dosis ebenso die Proliferation Antigen-spezifischer T-Zellen. Beide Substanzen wirkten antiproliferativ unabhängig von der Antigenpräsentation, aufgrund ihrer Fähigkeit, die Proliferation in Abwesenheit von professionellen Antigen-präsentierenden Zellen zu vermindern. Diese Eigenschaft weißt auf einen direkten Einfluß auf die T-Zell-Funktion hin. Die TRAIL-induzierte Hypoproliferation war assoziiert mit einer Herunterregulation der Zyklin-abhängigen Kinase CDK4 (engl.: cyclin dependent kinase 4), einem Schlüsselenzym für die nach T-Zell-Rezeptor-Stimulation einsetzende Transition von der G1- zur S-Phase des Zellzyklus. Inkubation mit Atorvastatin induzierte ebenso eine Verminderung von CDK4, begleitet von einer Erhöhung von p27Kip1. Die Atorvastatin-vermittelte Proliferations- und Zellzyklus-Blockade konnte durch Mevalonat rückgängig gemacht werden. Mevalonat ist ein Zwischenprodukt des HMG-CoA-Reduktaseweges. Atorvastatin scheint demnach einen direkten Einfluß auf diese Enzymkaskade zu haben, der wichtig für die Isoprenylierung von GTPase-Proteinen der Rho-Familie ist. T-Zell-Rezeptor-Stimulation führt zur Freisetzung von Kalzium aus intrazellulären Speichern und nachfolgend zur Öffnung transmembranöser Kalzium-Kanäle (sog. calcium release-activated calcium oder CRAC-Kanäle), die eine für die T-Zellaktivierung notwendige und anhaltende Erhöhung der intrazellulären Kalzium-Konzentration hervorruft. Nach Behandlung mit TRAIL wurde eine konzentrationsabhängige Inhibition des Einstroms extrazellulärer Kalzium-Ionen durch die CRAC-Kanäle beobachtet. Dies wurde mit löslichem TRAIL-Rezeptor-Fusionsprotein, einem TRAIL-Antagonisten, rückgängig gemacht. Die Blockade von Kalzium-abhängigen Aktivierungssignalen stellt damit möglicherweise einen primären immunregulatorischen Mechanismus für diese Todesliganden dar. Jedoch wurde keine Auswirkung von Atorvastatin auf die T-Zellaktivierung beobachtet, da der Einstrom von extrazellulärem Kalzium nicht beeinflußt wurde. Während Studien zum TRAIL-vermittelten Einfluß auf die T-Zell-Aktivierung und dem Zellzyklus erst in der präklinischen Phase sind, werden Statine, die ebenfalls den Zellzyklus beeinflussen, bereits in der Therapie anderer Erkrankungen angewand. Darüber hinaus werden derzeit bereits klinische Studien mit Statinen zur MS-Therapie durchgeführt. Weitere Untersuchungen zu den detaillierten Mechanismen antiproliferativer Substanzen mit potenziellem therapeutischen Effekt in der MS ermöglichen die Entwicklung von selektiveren immunomodulatorischen Therapien mit höherem therapeutischen Nutzen für MS-Patienten. / Multiple sclerosis (MS) is a heterogeneous disease of the central nervous system whose pathological mechanisms are far from completely understood. The current hypothesis is that pro-inflammatory T cells are orchestrating the pathogenesis of this condition. It is considered that a dysregulation in T cell control to be involved, with an imbalance in apoptosis-regulating molecules possibly playing a role. In fact, therapeutic strategies aim to reduce T cell activation, proliferation and cytokine production or to promote T cell elimination. The focus of this thesis was to identify the role of regulatory molecules for T cell survival in the immune pathogenesis of MS, and to investigate antiproliferative or apoptosis-promoting effects on T cells by potential therapeutic molecules. A limitation in the apoptotic regulation of autoreactive T cells in the periphery and in the CNS may contribute to the pathophysiology of MS. As key regulators of apoptosis, members of the Bcl-2 family were investigated in both MS patients and controls. These factors were examined in relation to the susceptibility of T cells, from both groups, towards activation-induced cell death (AICD). To mimic the in vivo elimination of antigen-reactive T cells, an in vitro model of AICD involving repetitive T cell receptor mediated stimulation was utilized. In fact, polyclonal T cells from MS patients showed a decreased susceptibility to undergo AICD as shown by both caspase activity (p=0.013) and DNA fragmentation (p=0.0071) assays. Furthermore, Bcl-XL protein levels, as measured by immunoblotting, were increased in the peripheral immune cells of MS patients (p=0.014). An inverse correlation observed between Bcl-XL levels and susceptibility of T cells to undergo AICD is in line with previous data on the significance of this anti-apoptotic protein in T cell resistance. Since this molecule has already been shown to aggravate the outcome of experimental autoimmune encephalitis, the animal model for MS, the observation of elevated Bcl-XL levels in patients offers perspectives towards therapeutic manipulation in MS. Apart from promoting apoptotic elimination, current therapeutic strategies aim at inhibiting activation and further proliferation of potentially harmful T cells. Based on clinical experience with rather non-selective therapies that promote T cell elimination, a therapeutic goal is to identify newer immunomodulatory substances with better selectivity in order to maximize the therapy's benefit to risk ratio. Thus, two different substances, both interfering with cell cycle regulation, were investigated. The first candidate was the recently discovered member of the TNF/NGF family of death ligands, TNF-related apoptosis inducing ligand (TRAIL) since it has been reported to have immunoregulatory functions and since human antigen-specific T cells were shown to be resistant towards apoptosis induction by this ligand. The second candidate drug with potential in MS therapy is atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase inhibitor and lipid-lowering drug, already indicated for anomalies in lipid metabolism. In order to prove the hypothesis that these substances interfere with T cell receptor signaling, human antigen-specific T cell lines from both MS patients and controls, characterized with regards to T helper differentiation and peptide specificity, were employed. Exogenous treatment of TRAIL resulted in an inhibition in proliferation, albeit to varying degrees (6.2% - 63.8% inhibition). Atorvastatin also inhibited proliferation of antigen-specific T cell lines in a dose-dependent manner. Both compounds induced hypoproliferation independently of antigen presentation, as shown by their ability to block T cell proliferation in response to direct T cell receptor engagement, thus indicating a direct influence on T cell function. The growth inhibition by TRAIL was associated with a downregulation of the cell cycle regulator CDK4, indicative of an inhibition of cell cycle progression at the G1/S transition. Incubating T cells with atorvastatin also induced a downregulation of CDK4 expression, which was accompanied by an upregulation of p27Kip1 expression. The atorvastatin-mediated inhibition in proliferation and cell cycle progression could be reversed by mevalonate, an intermediate product of the HMG-CoA reductase pathway, suggesting a direct involvement of atorvastatin in this pathway, necessary for the isoprenylation of small GTPase proteins of the Rho family. Utilizing a thapsigargin model of calcium influx to activate the same calcium-release activated calcium (CRAC) channels as T cell receptor-stimulation by antigen, an inhibition in calcium influx could be observed on pre-incubating T cells with TRAIL. Co-incubating with human recombinant TRAIL receptor 2 fusion protein, a competitive antagonist for TRAIL, reversed this inhibition. A direct influence on calcium influx is indicative of an influence of TRAIL on the activation status of human T cells. Therefore, TRAIL directly inhibits activation of these cells via blockade of calcium influx. However, no impact of atorvastatin on early T cell activation was observed, since calcium influx was unaffected. While TRAIL-mediated interference with T cell activation and further cell cycle progression is still in the pre-clinical phase, statins, which have also been shown here to interfere with the T cell cycle, are already employed in the clinic for other ailments. In fact, clinical trials are currently being undertaken with this group of drugs for MS. Further studies on detailed mechanisms of antiproliferative substances effective in MS will allow the development of highly selective immunomodulatory agents with increased beneficial profile as MS therapy.

CAR-T-Zell-Therapie ist eine vielversprechende neuartige Behandlungsform für Patienten mit aggressiven B-Zell Non-Hodgkin-Lymphomen (B-NHL). In dieser Arbeit wurde die anti-CXCR5 CAR-T-Zell-Therapie als Alternative zur anti-CD19 CAR-T-Zell-Therapie für die Behandlung von reifen B-NHLs untersucht. CXCR5 ist ein B-Zell-homing Rezeptor, der von reifen B Zellen und follikulären T-Helferzellen (TFH Zellen) exprimiert wird. TFH Zellen wurden als tumor-unterstützend in chronisch lymphatischer Leukämie (CLL) und im follikulären Lymphom (FL) beschrieben. Dieses Expressionsmuster erlaubt es, auf einzigartige Weise zeitgleich die malignen Zellen und die tumorunterstützende Mikroumgebung mithilfe von CAR-T-Zell-Therapie gerichtet gegen einen Chemokinrezeptor anzugreifen. Die wichtigsten Ergebnisse dieser Arbeit waren, dass (1) die anti-CXCR5 CAR T-Zellen zielgerichtet CXCR5 positive reife B-NHL Zelllinien und Patientenproben in vitro eliminierten und eine starke anti-Tumor Reaktivität in einem immundefizienten Xenotransplantationsmausmodell zeigten, (2) die anti-CXCR5 CAR T-Zellen zielgerichtet die tumorunterstützenden TFH Zellen in CLL und FL Patientenproben in vitro erkannten und dass (3) CXCR5 ein sicheres Expressionsprofil zeigte. CXCR5 war stark und häufig auf B-NHL exprimiert und die Expression auf gesundem Gewebe war auf lymphoide Zellen beschränkt. Zusammenfassend lässt sich sagen, dass die anti-CXCR5 CAR-T-Zell-Therapie eine neue Behandlungsmöglichkeit für Patienten mit reifen B-NHL darstellt, indem durch die anti-CXCR5 CAR-T Zellen sowohl der Tumor als auch ein Anteil der tumorunterstützende Mikroumgebung eliminiert werden. Im zweiten Teil der Arbeit wurde das Eμ-Tcl1 murine CLL Lymphommodell genutzt um die Auswirkung der Lymphomentwicklung auf die CXCR5+ T Zellen zu untersuchen. Mittels RNA-Einzelzell-Sequenzierung konnte ein profunder Einfluss des Lymphomwachstums auf das T Zell-Kompartiment der Mäuse, denen Eμ-Tcl1 Zellen gespritzt wurden, gezeigt werden. / CAR T cell therapy is a promising new treatment option for patients suffering from aggressive B non-Hodgkin lymphomas (NHLs). In CAR T cell therapy, patient-derived T cells are genetically modified to express a chimeric receptor commonly directed towards a surface antigen expressed by neoplastic cells. In this thesis, anti-CXCR5 CAR T cell therapy was investigated as an alternative to anti-CD19 CAR T cell therapy for the treatment of mature B-NHLs. CXCR5 is a B cell homing receptor expressed by mature B cells and follicular helper T (TFH) cells. TFH cells were described to support the tumor cells in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). This expression pattern allows simultaneous targeting of the malignant cells and the tumor-supporting microenvironment by CAR T cell therapy against a chemokine receptor in an unprecedented manner. Main findings included that (1) anti-CXCR5 CAR T cells targeted specifically CXCR5 expressing mature B-NHL cell lines and patient samples in vitro and showed strong in vivo anti-tumor reactivity in an immunodeficient xenograft mouse model, (2) anti-CXCR5 CAR T cells targeted tumor-supportive TFH cells derived from CLL and FL patient samples in vitro and (3) CXCR5 showed a safe expression profile. CXCR5 was strongly and frequently expressed by B-NHLs and its expression on healthy tissue was restricted to lymphoid cells. In summary, anti-CXCR5 CAR T cell therapy presents a novel treatment option for patients suffering from mature B-NHLs by eliminating the tumor and part of the tumor-supportive microenvironment. The second part of the project, the Eμ-Tcl1 murine lymphoma model, which mimics human CLL, was used to study the impact of lymphomagenesis on CXCR5+ T cells. Using single cell RNA sequencing, a profound influence of lymphoma growth on the T cell compartment in Eμ-Tcl1 tumor-challenged mice could be shown.